In a first, Amit Shah launches Hindi version of MBBS books in Bhopal. Read here | Mint – Mint

The Madhya Pradesh government has started an ambitious project wherein now medical students can opt for studying MBBS in Hindi, instead of English, as is the norm for the rest of the country. On Sunday, at an event in state capital Bhopal, Union Home Minister Amit Shah launched the Hindi version of three subjects.

The Hindi version of medical biochemistry, anatomy and medical physiology subject textbooks were released by Amit Shah. Madhya Pradesh Chief Minister Shivraj Singh Chouhan and state medical education minister Vishwas Sarang were also present at the event.

"Today Amit Shah has brought a new dawn in the lives of children of the poor, who could get admission to medical colleges but were caught in the web of English and many times could not pass exams and left their studies," CM Chouhan said.

Madhya Pradesh has become the first state in the country to start the MBBS course in Hindi, state Medical Education Minister Vishvas Sarang said on the occasion.

A team of 97 experts have been working on the preparation of books for the last 232 days at Gandhi Medical College, Bhopal. They have been translating the book from English to Hindi.

Madhya Pradesh medical education minister Vishwas Sarang on Sunday said that the move will bring a big change in the advancement of education in Hindi medium.

Speaking to ANI, Sarang said, "It is a big day. For the first time in the country, medical education in Hindi will begin in Madhya Pradesh. Home Minister Amit Shah and Chief Minister Shivraj Singh Chouhan will launch the Hindi versions of textbooks of all three subjects of the first year - Anatomy, Physiology and Biochemistry today."

"This is a matter of joy for me. It now becomes clear that if medical education is possible in Hindi, any course is possible in Hindi. This will bring a major change in the lives of youth, especially those from Hindi backgrounds," he added.

"It was not an easy task but we prepared it in very easy language. We have prepared it so that it will be helpful in the studies of the students," an expert involved in the translation told news agency ANI.

The expert further said the new edition of Medical Biochemistry contains the application of some new chapters which include Sodium, Potassium, Water Homeostasis, Biochemistry Techniques, Radiation, Radioisotopes and Environmental Pollutants and Toxins.

Besides, Several new line diagrams, tables and text boxes have been added to make information more memorable.

Similarly in the Anatomy edition, new chapters of surface anatomy have been added in both abdomen and lower limb sections. New line diagrams, CT's and MRI's diagram tables and flow charts are added to increase the retention of knowledge.

See the article here:
In a first, Amit Shah launches Hindi version of MBBS books in Bhopal. Read here | Mint - Mint

Vitamin B1 may decrease the chances of migraine headaches – Medical News Today

Migraine headaches can be painful and difficult to manage.

The specific symptoms and timing are different for each person affected.

Experts are still working to understand why migraine headaches happen and what preventative steps people can take.

A recent study published in Headache: The Journal of Head and Face Pain reports that dietary intake of the B vitamin thiamine may help prevent migraine in some people.

Experts say the information gained from this research indicates a protective factor that may help improve outcomes for people who experience migraine.

Migraine is a neurologic condition that causes severe headaches that are typically localized to one area of the head.

The pain can be intense and people sometimes can experience other symptoms such as nausea or vomiting. Migraine headaches can be related to specific triggers, such as stress or hormonal changes.

Diet is one area that can affect migraine headaches. However, the specifics are something that experts are still working to understand. Specific food triggers or preventative measures can be different for each person.

Dr. Clifford Segil, DO, a neurologist at Providence Saint Johns Health Center in California, noted a few examples of this to Medical News Today:

Dietary triggers are common for migraine. Wines, cheeses, and caffeine can trigger a migraine headache. I ask patients on their first visit with me to keep a headache journal to see if there are any medications that trigger headaches. Caffeine can both cause and help headaches, so it is hard to generalize if something like this causes or helps headaches.

People who experience migraine may work with their doctors and other specialists to identify headache triggers.

As more data emerges about the relationship between diet and migraine headaches, clinical recommendations for treatment may continue to change.

Researchers in the new particular study examined the association between two B vitamins, thiamine (vitamin B1) and riboflavin (vitamin B2), and the experience of severe headaches or migraine.

Researchers looked at data from participants in the National Health and Nutrition Examination Survey (NHANES) from 1999-2004 in their cross-sectional study.

Researchers included more than 13,000 participants in their analysis. Of these participants, 2,745 had experienced either a severe headache or migraine within the past three months. The researchers studied the 24-hour dietary intake of thiamine and riboflavin by looking at data collected from computer-assisted interviews of the participants.

They accounted for several factors, including participants ages, lifestyles, demographics, and comorbidities.

Researchers reported that higher amounts of thiamine in the diet were associated with lower chances of migraine. This was particularly true among female participants. However, the researchers did not find a significant decrease in risk related to riboflavin.

Dr. James Giordano, a professor of neurology and biochemistry at Georgetown University Medical Center in Washington, D.C., who was not involved in the study, noted the following to MNT:

This study provides important data to support that nutritional factors can be influential upon the induction of migraine headache. Of particular note is that this study demonstrated a statistically significant role of thiamine (vitamin B-1) in mitigating migraine. Thiamine has been shown to be particularly important in regulating brain levels of the neurotransmitter serotonin; abnormalities in serotonin function have been directly implicated in the pathophysiology of migraine.

The study did have some limitations.

First, the data relies on self-reporting from participants, which can be inaccurate. For example, when evaluating the incidence of migraine, there is some assumption that participants who reported a severe headache likely experienced a migraine. The 24-hour recall method also has the potential for errors in data collection.

In addition, the interviews did not include questions about all intestinal diseases and researchers did not look into dietary patterns.

Researchers also did not look at the intake of dietary supplements, which could have impacted the intake of thiamine and riboflavin.

Finally, there is the risk of errors based on the analysis techniques used and this type of study cannot prove that lack of thiamine causes migraine.

Overall, the study notes the impact thiamine may have on migraine headaches. It could open the door to further research in this area and later guide specific clinical recommendations.

Giordano noted the following:

Taken together, it may be that thiamine could provide a useful dietary supplement for migraine-suffering individuals who may be mild to moderately magnesium deficient or who have metabolic disturbances of calcium and magnesium metabolism.

He also noted the following areas for continued research:

While research is most certainly interesting and important, additional studies should be conducted to determine more specific roles for thiamine, as well as other vitamin co-factors that may be clinically useful in preventing or lessening migraine.

More here:
Vitamin B1 may decrease the chances of migraine headaches - Medical News Today

Recognition for three ILS scientists – The New Indian Express

By Express News Service

BHUBANESWAR: Three scientists of Institute of Life Sciences (ILS) are among the worlds most influential scientific minds in 2022, as per a report published by Stanford University. The report that classified scientists in 22 scientific fields and 176 sub-fields has enlisted in-charge Director of ILS Prof Pulok Kumar Mukherjee, scientists Sanjeeb Sahoo and Amaresh Panda for their outstanding research in the field of drug discovery, biochemistry and molecular biology.

Prof Mukherjee is working on traditional medicine-inspired drug discovery and development from Indian medicinal plants with major emphasis on their validation, formulation, and standardisation. Sahoo focuses on nano-technology-based targeted drug delivery to tumour tissues whereby using the techniques, one can kill cancer cells in a lower dose with less toxicity to the normal tissue.

Similarly, Pandas research group has been working on the role of poorly characterised circular RNAs in muscle regeneration and insulin bio-synthesis. The new molecular mechanisms identified during his work contribute valuable knowledge of the post-transcriptional processes that influence human health and disease.

See the original post here:
Recognition for three ILS scientists - The New Indian Express

New Center Leads Collaborative Research to Improve Firefighter Health – University of Arizona

The new Center for Firefighter Health Collaborative Researchin the University of Arizona Mel and Enid Zuckerman College of Public Health at the University of Arizona Health Sciences will allow researchers to expand their work with firefighters and fire departments to study the occupational health risks firefighters face.

The center, recently approved by the UArizona Office of Research, Innovation and Impact, builds on years of firefighter health research conducted by Zuckerman College of Public Health faculty in close collaboration with fire departments. Some of that research has already had a positive impact on firefighter health, including helping inform the International Agency for Research on Cancers decision to classify occupational exposure as a firefighter as carcinogenic, changing the previous classification of possibly carcinogenic.

This new center focuses our efforts to find answers to the health questions that our firefighter partners are asking by bringing together the researchers who are working with firefighters on a range of issues, said Jefferey L. Burgess, MD, MS, MPH, professor in the Zuckerman College of Public Health. Our community-engaged research with firefighters is at the heart of the center.

Research conducted at the Center for Firefighter Health Collaborative Research will build on previous studies and provide a database to help inform decisions, practices and policies to improve firefighter safety and health.

The center researchers and their teams have brought in over $50 million in grant funding awards since 2015 and resulted in more than 45 research publications that have informed practice and policy for firefighters and other essential workers.

Our collaboration with researchers from the University of Arizona Health Sciences has already delivered real benefits for our firefighters. I am proud that we can be part of a larger effort that advances health promotion and policy for all firefighters, said Tucson Fire Department Capt. John Gulotta. This collaborative effort is unique because stakeholder perspectives, activities and opinions from all levels of the fire service from frontline firefighters to senior leadership are represented. This approach improves the chance for successful change in the fire service safety culture.

We have forged strong relationships with the Tucson Fire Department and other fire departments that enable this research, said Dr. Burgess, who is also a member of the BIO5 Institute. At the same time, were able to draw on a range of public health expertise and exposure science knowledge at the University of Arizona Health Sciences and other collaborating universities that make it possible to do this work and answer these important occupational health questions.

Other College of Public Health researchers working with the Center for Firefighter Health Collaborative Research include associate professor Kate Ellingson, PhD; assistant professor and BIO5 Institute member Leslie Farland, ScD, MSc; assistant professor Melissa Furlong, PhD; associate professor Patricia Haynes, PhD, CBSM; and assistant professor Yiwen Liu, PhD. They work closely with firefighter partners including Gulotta; Capt. Jamie Gabriel from the Los Angeles County Fire Department; retired Capt. Jeff Hughes from the Orange County Fire Authority; Derek Urwin, PhD, engineer with the Los Angeles County Fire Department and assistant adjunct professor of chemistry and biochemistry at UCLA; and Darin Wallentine, deputy fire chief of administrative services for the Sarasota County Fire Department in Florida.

Among many ongoing areas of research, Dr. Haynes works closely with the Tucson Fire Department to provide mental health services for firefighters, who often experience unusual levels of stress on the job. She worked with the Tucson Fire Department to develop a Peer Operational Support Team, or POST, where trained peers connect with their colleagues to provide resources after potentially traumatic calls.

I am fortunate to work with Tucson Fire, and the collaborative mental health programming we implemented has made a difference, Dr. Haynes said. Our POST program has bridged employees to mental health care and reduced the stigma sometimes associated with seeking care.

Moving forward, researchers at the center will build on existing partnerships and expand collaborations with other fire departments and wildland firefighting agencies, growing their reach and expertise to change policy and practice that will lead to better health outcomes for firefighters.

All of us in the college are very proud of what our faculty and their firefighter colleagues have accomplished, said Iman Hakim, MD, PhD,dean of the Zuckerman College of Public Health, They have been at the forefront of firefighter health research in many ways, with strong partners in the Tucson Fire Department, and they are really making a difference. Im very pleased that the new center will provide a focus for this expertise and continue our progress to keep firefighters healthy.

Follow this link:
New Center Leads Collaborative Research to Improve Firefighter Health - University of Arizona

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS…

NEW YORK & CAMBRIDGE, England--(BUSINESS WIRE)--Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants. Veteran biotech executives Usman Oz Azam, M.D., Chief Executive Officer, and Fred Grossman, D.O., FAPA, Chief Medical Officer, lead the company.

Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms. The platform is being used to identify therapeutic fungal alkaloids, cannabinoids, and other small molecules that may exhibit enhanced efficacy and safety. In addition, the platform is designed to discover novel small molecules that may exhibit a therapeutic benefit.

There is an enormous medical need for safe and effective therapeutics that treat neuropsychiatric and neurologic disorders and we believe genetic engineering provides the answer, said Dr. Azam, Empyreans Chief Executive Officer. By applying our genetic engineering platform to make precise modifications to the genomes of fungi and plants, we can change the amount and kind of neuroactive small molecules they produce, with the goal of developing safe and effective treatments for difficult-to-treat diseases of the CNS.

The companys developmental pipeline includes fungal alkaloids, cannabinoids, and other neuroactive compounds, such as N,N-Dimethyltryptamine (DMT), for the potential treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), neurologic disorders, substance abuse and dependence, and chronic pain. Investigational New Drug (IND) enabling studies of the companys first genetically engineered encapsulated mushroom drug product are currently underway, and the company aims to enter the clinic for MDD in 2023.

Fungal alkaloids and cannabinoids have shown promise in treating depression, PTSD, anxiety, and other neuropsychiatric and neurologic disorders, said Dr. Grossman, Empyreans Chief Medical Officer. We believe our approach of genetically engineering fungi and plants can improve their safety and efficacy and will ultimately help to address the substantial unmet medical need in patients who suffer from these diseases.

As part of its genetic engineering platform, the company has licensed CRISPR/Cas9 technology from ERS Genomics for genetic engineering applications related to its therapeutic pipeline.

Dr. Azam was previously President and Chief Executive Officer of Tmunity Therapeutics, a biotech developing genetically engineered cell therapies for applications in cancer. Before Tmunity, he was Global Head of Cell & Gene Therapies at Novartis, where he was responsible for commercial operations, business development licensing, new product commercialization, clinical development, regulatory affairs, and other aspects of the global cell and gene therapies business. He was Chief Executive Officer of Novaccel Therapeutics, Chief Medical Officer of Aspreva Pharmaceuticals, and earlier in his career, held positions at Johnson & Johnson, GSK, and Pfizer. Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.

Before joining Empyrean, Dr. Grossman was Chief Medical Officer of Mesoblast Ltd. and President and Chief Medical Officer of Glenmark Pharmaceuticals. He has held executive leadership positions in large pharmaceutical companies, including Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He has been responsible for leading the development, approval, and supporting the launch of numerous global medications addressing significant unmet medical needs across therapeutic areas, particularly in the CNS. He has held academic appointments and has authored numerous scientific publications. He was trained in psychiatry at Hahnemann University in Philadelphia and at the National Institute of Mental Health in Bethesda, Maryland and completed a Fellowship in the Section on Clinical Pharmacology at the National Institutes of Health. Dr. Grossman is a board-certified psychiatrist and Fellow of the American Psychiatric Association.

About Empyrean Neuroscience

Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders. Through precision genetic modification, transformation, and regeneration of fungi and plants, the platform allows for the creation of small molecule therapeutics. In addition, the platform enables the discovery of novel small molecules that may exhibit therapeutic properties. The company is based in New York City and Cambridge, UK.

Link:
Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS...

COVID-19 Linked to Excessive Destruction of Connections Between Nerve Cells – Neuroscience News

Summary: COVID-19 infection causes microglia to excessively engulf synaptic structures and the upregulation of factors involved in phagocytosis.

Source: Karolinska Institute

Researchers at Karolinska Institutet have in a new study used cellular reprogramming to create human three-dimensional brain models and infected these models with SARS-CoV-2.

In infected models, the brain immune cells excessively eliminated synapses and acquired a gene expression pattern mimicking what has been observed in neurodegenerative disorders.

The findings could help to identify new treatments against persistent cognitive symptoms after a COVID-19 infection.

Multiple studies have reported persistent cognitive symptoms after a COVID-19 infection but the underlying mechanisms for this remains unknown.

The researchers behind the study, published as an Immediate Communication in the journalMolecular Psychiatry, have from human induced pluripotent stem (iPS) cells created three-dimensional models of the brain in a dishso-called brain organoids.

The model differs from previous organoid models as the researchers also included the brainimmune cellsmicrogliain the model.

In the infected models, microglia excessively engulfed synaptic structures and displayed upregulation of factors involved in phagocytosis. The developed model and the findings in the study could help to guide future efforts to target cognitive symptoms in the aftermath of COVID-19 and other neuroinvasive viral infections.

Cognitive deficits after the infection

Interestingly, our results to a large extent mimic what has recently been observed in mouse models infected with other neuroinvasive RNA viruses such as the West Nile virus. These viruses are also linked to residual cognitive deficits after the infection, and a persisting activation of microglia leading to an excessive engulfment of synapses, which has been suggested to drive these symptoms.

Multiple studies have now also reported remaining cognitive symptoms after a COVID-19 infection, as well as an increased risk of receiving a diagnosis of a disorder characterized by cognitive symptoms, says co-first author of the study Samudyata, postdoctoral fellow in Sellgren lab at the Department of Physiology and Pharmacology at Karolinska Institutet.

Connections to Parkinsons and Alzheimers disease

Microglia are the resident immune cells of the brain but also carries out important regulatory functions of the neuronal circuitries in the developing and adultbrain. One of these crucial functions is to engulf unwanted synapses, a process that is believed to improve and maintain cognitive functions.

However, excessive engulfment of synapses has been linked to both neurodevelopmental disorders, such as schizophrenia, as well as to neurodegenerative disorders including Alzheimers disease.

By sequencing genes insingle cells, the authors could also study how different cell types in the model responded to the virus.

Microglia displayed a distinct gene signature largely characterized by an upregulation of interferon-responsive genes, and included pathways previously linked to neurodegenerative disorders such as Parkinsons and Alzheimers disease.

This signature was also observed at a later time-point when the virus load was minimal, says co-author of the study Susmita Malwade, doctoral student in Sellgren lab at the Department of Physiology and Pharmacology at Karolinska Institutet.

The researchers will now study how different pharmacological approaches can reverse the observed changes in the infected models.

Author: Press OfficeSource: Karolinska InstituteContact: Press Office Karolinska InstituteImage: The image is in the public domain

Original Research: Open access.SARS-CoV-2 promotes microglial synapse elimination in human brain organoids by Samudyata et al. Molecular Psychiatry

Abstract

SARS-CoV-2 promotes microglial synapse elimination in human brain organoids

Neuropsychiatric manifestations are common in both the acute and post-acute phase of SARS-CoV-2 infection, but the mechanisms of these effects are unknown.

In a newly established brain organoid model with innately developing microglia, we demonstrate that SARS-CoV-2 infection initiate neuronal cell death and cause a loss of post-synaptic termini.

Despite limited neurotropism and a decelerating viral replication, we observe a threefold increase in microglial engulfment of postsynaptic termini after SARS-CoV-2 exposure.

We define the microglial responses to SARS-CoV-2 infection by single cell transcriptomic profiling and observe an upregulation of interferon-responsive genes as well as genes promoting migration and synapse engulfment.

To a large extent, SARS-CoV-2 exposed microglia adopt a transcriptomic profile overlapping with neurodegenerative disorders that display an early synapse loss as well as an increased incident risk after a SARS-CoV-2 infection.

Our results reveal that brain organoids infected with SARS-CoV-2 display disruption in circuit integrity via microglia-mediated synapse elimination and identifies a potential novel mechanism contributing to cognitive impairments in patients recovering from COVID-19.

More:
COVID-19 Linked to Excessive Destruction of Connections Between Nerve Cells - Neuroscience News

Neuroscience Research Fellow Discovers the Power of Perseverance – St. Lawrence University Saints

Nadiana Acevedo 24 isnt afraid of a challenge. When she set out to investigate the effects of an anti-cancer drug this summer, she discovered that sometimes the best learning experiences can come from trial and error.

As part of the Collegiate Science and Technology Entry Program (CSTEP), Nadiana spent eight weeks conducting research alongside Professor of Biology and Psychology Ana Estevez. The scholar program is designed to increase the number of historically underrepresented and economically disadvantaged students in mathematics, science, technology, and health-related fields.

Nadiana shared what fueled her curiosity for research and how she defines success.

(Note: Responses have been edited for length.)

Major: Neuroscience

Hometown: Buffalo, New York

Project Title: "Observing Cell Viability of HT-22 Hippocampal Cells When Exposed to Anti-Cancer Dye MKT-077"

The focus of my research is looking at an anti-cancer dye, MKT-077. This dye is known to be selective to cancer cells meaning it only kills cancer cells. I am testing the drug on a mouse hippocampal neuronal cell line called HT-22 (brain cells) to observe the drug's effect on the cells' viability.

Cancer research is challenging and exciting because it is full of trial and error. I was interested in looking at how this drug would affect neuronal cells because there is a lack of data specific to neurons. I was intrigued that MKT-077 is selective to cancer cells because other drugs kill both healthy and cancerous cells.

The research process was difficult at times because my mentor and I did not know how the MKT-077 would affect the HT-22 cells. The data seemed off in the beginning. We weren't sure if there was an issue with fluorescence when the microplate reader was collecting data. We had to run a test to determine if the MKT-077 had its own fluorescence that would interfere with the dye we used to measure viability. The data showed no conflict between the MKT-077 and the CYQUANT dye we used to measure cell viability.

I did not get discouraged by the research outcomes and was able to complete my summer research and presented my findings.

Dr. Ana Estevez is an amazing advisor and mentor. I built a connection with her over the summer and learned many skills. She has helped me become a well-rounded researcher.

It is possible to succeed and gain knowledge regardless of the data outcome. There is always something to gain from every experience and there is always something new to discover.

Learn About Research

Learn About Neuroscience

See the article here:
Neuroscience Research Fellow Discovers the Power of Perseverance - St. Lawrence University Saints

NUCALM WILL UNLEASH THE POWER OF YOUR MENTAL STATE AT THE 2022 NEUROSCIENCE SUMMIT – PR Newswire

LOS ANGELES, Oct. 18, 2022 /PRNewswire/ -- NuCalm CEO Jim Poole will be this year's featured presenter at the 2022 Neuroscience Summit. The highly anticipated event will be broadcasting live, worldwide from October 20th to October 23rd, available on Roku TV and other streaming platforms. The brain health and wellness event features a stellar lineup of New York Times Bestselling authors, Harvard scientists and mental health experts. Complete details are on the event's website: http://www.nsciencesummit.com.

NuCalm research and their studies have led to a patented neuroscience technology unleashing the brain's unlimited potential. By participating in this year's summit, thousands of new users will have the chance see how they can take control of their lives and achieve their goals. NuCalm's unprecedented work in neuroscience gives individuals the power to improve memory, accelerate the learning process and most importantly the ability to harness calm. Calm, the absence of harmful emotions such as fear, nervousness, anxiety, panic or anger, can be leveraged to provide emotional intelligence to help leaders make the decisions necessary to achieve success.

NuCalm's CEO, Jim Poole, extols the impact that the 2022 Neuroscience Summit will have by saying, "This year's event will offer thousands of people a look into our neuroscience platform that changes the game for so many people. The abilities that NuCalm unlocks is the beginning of unleashing the full human potential." Poole said, "Through decades of research and development, we've made it possible to construct and consciously control the most complicated and powerful computing system, your brain. Drugs and stimulants are no longer necessary for one to leverage their brain wave frequencies to overcome obstacles and achieve their goals."

To date, millions of people across the globe have benefitted from regular use of NuCalm (www.NuCalm.com). This patented, clinically proven technology allows you to flip the switch from stress to rest and recovery within minutes, without drugs or side-effects. Since 2009, NuCalm has been used in over two million surgical procedures and used bysports teams, the military, the FBI, cancer patients, PTSD sufferers, pilots, busy executives and many others.

Contact for NuCalm:Alfred HoptonCapstone Communications Company[emailprotected]

Laurie D. MuslowIt's All Good Entertainment Inc.818-808-0868 Office Direct[emailprotected]

David PooleChief Business OfficerNuCalm617-259-0877[emailprotected]

For more info visit http://www.nucalm.comor call 800-810-1701 to speak to a representative.

SOURCE NuCalm

Here is the original post:
NUCALM WILL UNLEASH THE POWER OF YOUR MENTAL STATE AT THE 2022 NEUROSCIENCE SUMMIT - PR Newswire

A New Protein That May Contribute to Alzheimers Disease Identified – Neuroscience News

Summary: The GM2A protein reduces neural firing and induces a loss of neurite integrity.

Source: Brigham and Womens Hospital

Alzheimers disease (AD) currently has no cure and is predicted to affect over 100 million people worldwide by 2050.

Ongoing research is focused on two key neurotoxic proteins: amyloid beta (A) and tau. While these proteins have been shown to be associated with AD, for some people with the disease, the levels of A and tau do not consistently explain or correlate with the severity of cognitive decline.

To identify other proteins that may be directly involved with fundamental aspects of AD, like synaptic loss and neurodegeneration, investigators at Brigham and Womens Hospital, a founding member of the Mass General Brigham healthcare system, exposed laboratory neurons to human brain extracts from about 40 people who either had AD, were protected from AD despite having high A and tau levels, or were protected from AD with little or no A and tau in their brains.

The researchers identified and validated ganglioside GM2 activator (GM2A) as a protein able to reduce neuronal firing and induce a loss of neurite integrity. These protein characteristics may contribute to the cause of AD, progression of the disease, or both.

Our data helps identify a new and potentially important protein that may be associated with the pathogenesis of Alzheimers disease, said senior author Tracy Young-Pearse, PhD, from the Department of Neurology.

Interestingly, GM2A has been previously implicated as a causative agent in a lysosomal storage disorder very similar to Tay-Sachs disease, another condition like AD that destroys neurons.

Author: Haley BridgerSource: Brigham and Womens HospitalContact: Haley Bridger Brigham and Womens HospitalImage: The image is in the public domain

Original Research: Open access,Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity by Tracy Young-Pearse et al. Molecular Neurodegeneration

Abstract

Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity

Alzheimers Disease (AD) affects millions globally, but therapy development is lagging. New experimental systems that monitor neuronal functions in conditions approximating the AD brain may be beneficial for identifying new therapeutic strategies.

We expose cultured neurons to aqueous-soluble human brain extract from 43 individuals across a spectrum of AD pathology. Multi-electrode arrays (MEAs) and live-cell imaging were used to assess neuronal firing and neurite integrity (NI), respectively, following treatments of rat cortical neurons (MEA) and human iPSC-derived neurons (iN) with human brain extracts.

We observe associations between spontaneous activity and A42:40 levels, between neurite integrity and oligomeric A, and between neurite integrity and tau levels present in the brain extracts. However, these associations with A and tau do not fully account for the effects observed. Proteomic profiling of the brain extracts revealed additional candidates correlated with neuronal structure and activity. Neurotoxicity in MEA and NI assays was associated with proteins implicated in lysosomal storage disorders, while neuroprotection was associated with proteins of the WAVE regulatory complex controlling actin cytoskeleton dynamics. Elevated ganglioside GM2 activator (GM2A) associates with reductions in both NI and MEA activity, and cell-derived GM2A alone is sufficient to induce a loss of neurite integrity and a reduction in neuronal firing.

The techniques and data herein introduce a system for modeling neuronal vulnerability in response to factors in the human brain and provide insights into proteins potentially contributing to AD pathogenesis.

Continue reading here:
A New Protein That May Contribute to Alzheimers Disease Identified - Neuroscience News

Reductionism as a Dead End in Neuroscience Captured in an Essay – Walter Bradley Center for Natural and Artificial Intelligence

University of Sussex professor of cognitive and computational neuroscience Anil K. Seth, during a routine dismissal of Ren Descartes (15961650), assures us, It looks like scientists and philosophers might have made consciousness far more mysterious than it needs to be.

More mysterious than it needs to be?

As noted earlier, what makes understanding the human mind necessarily complex is that it is both the entity we are trying to perceive and the tool by which we hope to perceive it. Such a problem is like trying to imagine a five-dimensional box in relation to the real world. Unlike the five-dimensional box, consciousness is part of the life experience of every human being.

How would Dr. Seth unravel the problem? In a classic essay, he reassures us,

Once, biochemists doubted that biological mechanisms could ever explain the property of being alive. Today, although our understanding remains incomplete, this initial sense of mystery has largely dissolved. Biologists have simply gotten on with the business of explaining the various properties of living systems in terms of underlying mechanisms: metabolism, homeostasis, reproduction and so on. An important lesson here is that life is not one thing rather, it has many potentially separable aspects.

Well, wait. We know a great deal more than we did centuries ago about the circumstances that enable a life form to keep itself alive and pass on that state to a further generation. But we are still at a complete loss as to the origin of life.

This is despite hundreds of speculative papers published every year. Eminent chemist James Tour has often remarked on well, expostulated about this problem. Its fascinating. It is especially relevant to the search for life on other planets in our galaxy. But looking for evidence of lifes existence is quite different from explaining lifes origin.

Origin of consciousness is in roughly the same state as origin of life. We have vast amounts of useful information about being conscious but we have no idea how it comes about.

What does Dr. Seth say about consciousness (or selfhood)?

Of the many distinctive experiences within our inner universes, one is very special. This is the experience of being you. Its tempting to take experiences of selfhood for granted, since they always seem to be present, and we usually feel a sense of continuity in our subjective existence (except, of course, when emerging from general anaesthesia). But just as consciousness is not just one thing, conscious selfhood is also best understood as a complex construction generated by the brain.

There is the bodily self, which is the experience of being a body and of having a particular body. There is the perspectival self, which is the experience of perceiving the world from a particular first-person point of view. The volitional self involves experiences of intention and of agency of urges to do this or that, and of being the causes of things that happen. At higher levels, we encounter narrative and social selves. The narrative self is where the I comes in, as the experience of being a continuous and distinctive person over time, built from a rich set of autobiographical memories. And the social self is that aspect of self-experience that is refracted through the perceived minds of others, shaped by our unique social milieu.

In daily life, it can be hard to differentiate these dimensions of selfhood.

The problem isnt so much that it is hard to differentiate these dimensions of selfhood as that it is hard to believe that a simple, reductionist approach to the question will provide much insight.

For example, Dr. Seth writes, The specific experience of being you (or me) is nothing more than the brains best guess of the causes of self-related sensory signals. That seems inconsistent with the council of selves that Dr. Seth himself sketches out in the paragraph quoted above. If he is right, your local town council votes may be less frenetic at any given time than what is going on in your own mind but that is not an argument for reductionism.

It becomes even more confusing when Dr. Seth tells us,

This returns us one last time to Descartes. In dissociating mind from body, he argued that non-human animals were nothing more than beast machines without any inner universe. In his view, basic processes of physiological regulation had little or nothing to do with mind or consciousness. Ive come to think the opposite. It now seems to me that fundamental aspects of our experiences of conscious selfhood might depend on control-oriented predictive perception of our messy physiology, of our animal blood and guts. We are conscious selves because we too are beast machines self-sustaining flesh-bags that care about their own persistence.

So, contemplating the vast mystery as well as complexity of consciousness, Dr. Seth asserts that it shows that we too are beast machines.

Actually, it provides a convincing demonstration of how reductionism does not work well in neuroscience. At most, it would mean that animal consciousness is more complex than we have earlier supposed. For that, at least, we have a growing body of evidence.

You may also wish to read: Psychiatry has always been difficult but its unclear how trashing almost every philosophical tradition from which it is approached will really help. Understanding the human mind is necessarily complex because it is both what we are trying to perceive and the tool by which we hope to perceive it.

Read more:
Reductionism as a Dead End in Neuroscience Captured in an Essay - Walter Bradley Center for Natural and Artificial Intelligence